Intelligence Feed event · Equity · 2026-10-21

    HUTCHMED closes KRAS-EGFR conjugate license to GSK outside China

    Question

    HUTCHMED closes KRAS-EGFR conjugate license to GSK outside China

    Direct answer

    The license monetizes HCM's pipeline and gives GSK an oncology asset with worldwide ex-China rights, which can support HCM cash value and GSK pipeline optionality.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-21
    Published
    2026-10-21
    Revision
    1 · 2026-10-21

    Cite as: Market Ontology, “HUTCHMED closes KRAS-EGFR conjugate license to GSK outside China”, revision 1, evidence through 2026-10-21. https://marketontology.com/market-events/2026-10-21/hutchmed-closes-kras-egfr-conjugate-license-to-gsk-outside-china-02f3d0

    EQUITY
    HUTCHMED closes KRAS-EGFR conjugate license to GSK outside China
    The license monetizes HCM's pipeline and gives GSK an oncology asset with worldwide ex-China rights, which can support HCM cash value and GSK pipeline optionality.
    HCMGSK
    Impact
    52
    YESTERDAY
    SIG
    75%
    HCMGSK
    HUTCHMED closes KRAS-EGFR conjugate license to GSK outside China
    The license monetizes HCM's pipeline and gives GSK an oncology asset with worldwide ex-China rights, which can support HCM cash value and GSK pipeline optionality.
    → The license monetizes HCM's pipeline and gives GSK an oncology asset with worldwide ex-China rights, which can support HCM cash value and GSK pipeline optionality.
    Impact
    The license monetizes HCM's pipeline and gives GSK an oncology asset with worldwide ex-China rights, which can support HCM cash value and GSK pipeline optionality.
    Affected
    HCMGSK
    Transmission
    The license monetizes HCM's pipeline and gives GSK an oncology asset with worldwide ex-China rights, which can support HCM cash value and GSK pipeline optionality.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMupfront cash and pipeline de-risking via exclusive license monetizationUp1-4wHUTCHMED will receive $110 million upfront.
    GSKoncology pipeline optionality via worldwide rights outside Greater China and TaiwanMixed1-4wGSK subsidiary gets worldwide rights excluding Greater China and Taiwan to develop and commercialize HMPL-A830.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month